Related Experiment Video
Updated: Jul 19, 2026
12:03
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Myocardial infarction. Effects of beta-blockade
1Department of Medicine, University of Gothenburg, Sahlgrenska Hospital, Sweden.
Circulation
|December 1, 1991
Summary
Beta-blocker therapy significantly reduces mortality and morbidity after myocardial infarction. Early and late treatment is crucial, as withdrawal may increase mortality, underscoring the importance of continuous beta-blocker use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The beneficial effects of beta-blockade post-myocardial infarction were proposed in the 1960s but definitively proven in 1981.
- Beta-blocker treatment is now a well-established standard for both acute and stable post-myocardial infarction patients.
Purpose of the Study:
- To review early and late treatment aspects of beta-adrenoceptor blockers in myocardial infarction.
- To discuss the cardioprotective effects, mortality, and morbidity benefits of beta-blockers.
Main Methods:
- Review of large clinical trials and pooled data on beta-blocker efficacy.
- Analysis of specific beta-blockers (propranolol, timolol, metoprolol) and their properties (lipophilicity, intrinsic sympathomimetic activity).
Main Results:
- Beta-blockers reduce mortality and morbidity in acute and stable post-myocardial infarction phases.
- Non-cardioselective and beta 1-selective beta-blockers without intrinsic sympathomimetic activity show impressive effects.
- Acute blockade reduces complications like chest pain and ventricular arrhythmias.
Conclusions:
- Continuous beta-blocker treatment is vital post-myocardial infarction.
- Withdrawal of beta-blockers after treatment cessation may increase mortality, even with measures to prevent withdrawal phenomena.
- Cardioprotective effects are not universal class effects; specific drug properties matter.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...